AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30661701 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized nutrition advice combined with vitamin K1, Ca and vitamin D
Number of subjects: 71
Study 30661701 — intervention group
Group type: COMPARATOR
Intervention: Usual care at the orthopedic ward (Control)
Number of subjects: 71
Study 30126559 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AF/AFL
Number of subjects: 871
Study 30126559 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident AF/AFL
Number of subjects: 871
Study 27669155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200mg/day
Number of subjects: 548
Study 27669155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400mg/day
Number of subjects: 548
Study 27669155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 24448173 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 119
Study 22486728 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fibre post
Number of subjects: 80
Study 22486728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast Ni‐Cr alloy post and core
Number of subjects: 80
Study 20455882 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day with reduced-exposure CsA
Number of subjects: 833
Study 20455882 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3.0 mg/day with reduced-exposure CsA
Number of subjects: 833
Study 20455882 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) 1.44 g/day plus standard-exposure CsA
Number of subjects: 833
Study 20455882 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with progressive reduction in CsA exposure
Number of subjects: 833
Study 17678730 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 103
Study 17678730 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 103
Study 15642018 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented visual feedback (FB) group using virtual reality (VR) system (DentSim)
Number of subjects: 0
Study 15642018 — intervention group
Group type: EXPERIMENTAL
Intervention: No augmented feedback (no-FB) group
Number of subjects: 0
Study 15642018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 12142815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 5 mg/kg daily
Number of subjects: 22
Study 12142815 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 10 mg/kg daily
Number of subjects: 22
Study 12142815 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily
Number of subjects: 22
Study 12142815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12142815 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (both doses) and Omeprazole
Number of subjects: 22
Study 10862313 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance (OGTT)
Number of subjects: 1198
Study 10862313 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1198
Study 10862313 — intervention group
Group type: COMPARATOR
Intervention: Overall population without diabetes
Number of subjects: 1198
Study 10862313 — intervention group
Group type: COMPARATOR
Intervention: Known type-2 diabetes
Number of subjects: 1198
Study 10862313 — intervention group
Group type: COMPARATOR
Intervention: Newly detected type-2 diabetes
Number of subjects: 1198
Study 7777127 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized clinical examination
Number of subjects: 1270
Study 2155457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ademetionin
Number of subjects: 9
Study 2155457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 537572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 12
Study 537572 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 12
Study 30889096 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d phytoSERM
Number of subjects: 71
Study 30889096 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d phytoSERM
Number of subjects: 71
Study 30889096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 30204859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention (weekly dietetic consultation, energy-protein-enriched diet, and ONS 400 mL per day for 3 months)
Number of subjects: 152
Study 30204859 — intervention group
Group type: COMPARATOR
Intervention: Usual nutritional care (control)
Number of subjects: 152
Study 30204859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention
Number of subjects: 152
Study 26576820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 196
Study 26576820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 196
Study 26576820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (cognitive behavior therapy and fluoxetine)
Number of subjects: 196
Study 26576820 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 196
Study 24988873 — intervention group
Group type: COMPARATOR
Intervention: 7-day PPI triple therapy
Number of subjects: 332
Study 24988873 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy
Number of subjects: 332
Study 24988873 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-day sequential therapy
Number of subjects: 332
Study 23148456 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating HIV care/treatment into family planning services
Number of subjects: 0
Study 23148456 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating HIV care/treatment into postnatal care services
Number of subjects: 0
Study 23148456 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 0
Study 19450880 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 15
Study 19450880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 15
Study 19450880 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 15
Study 19450880 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 15
Study 19450880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 15
Study 17452677 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus gemcitabine
Number of subjects: 569
Study 17452677 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 569
Study 15370581 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, daily subcutaneous injections for 4 weeks
Number of subjects: 20
Study 15370581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15370581 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 20
Study 12405553 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6mg)
Number of subjects: 12
Study 12405553 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin with Sunglasses (6mg)
Number of subjects: 12
Study 12405553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10440909 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 75
Study 7869203 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 26
Study 7869203 — intervention group
Group type: COMPARATOR
Intervention: Conventional intermittent mandatory ventilation (IMV)
Number of subjects: 26
Study 2220335 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopantomography
Number of subjects: 53
Study 2220335 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial radiography
Number of subjects: 53
Study 2220335 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmaxillary radiography
Number of subjects: 53
Study 2220335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiographic techniques
Number of subjects: 53
Study 2220335 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion in the condyle
Number of subjects: 53
Study 2220335 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on definite changes in the condyle
Number of subjects: 53
Study 366350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (300 microgram/day)
Number of subjects: 22
Study 366350 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 22
Study 31774842 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily educational text messages on diabetes for six months (Intervention)
Number of subjects: 216
Study 31774842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 216
Study 31774842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (text messaging)
Number of subjects: 216
Study 28922519 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil treatment
Number of subjects: 831
Study 28922519 — intervention group
Group type: COMPARATOR
Intervention: HOFA treatment
Number of subjects: 831
Study 25569810 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation
Number of subjects: 61
Study 25569810 — intervention group
Group type: COMPARATOR
Intervention: Control (physician-directed weaning)
Number of subjects: 61
Study 23418298 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-based algorithm for antibiotic therapy
Number of subjects: 31
Study 23418298 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical judgement without procalcitonin reference (Control)
Number of subjects: 31
Study 20502929 — intervention group
Group type: EXPERIMENTAL
Intervention: L. paracasei GMNL‐33
Number of subjects: 78
Study 20502929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 19905943 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment (scaling and root planing) before 21 weeks of gestation
Number of subjects: 823
Study 19905943 — intervention group
Group type: COMPARATOR
Intervention: Control group (periodontal treatment after delivery)
Number of subjects: 823
Study 17099008 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose all-trans retinoic acid (HD-ATRA) [2 mg/kg/d]
Number of subjects: 148
Study 17099008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose all-trans retinoic acid (LD-ATRA) [1 mg/kg/d]
Number of subjects: 148
Study 17099008 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid (13-cRA) [1 mg/kg/d]
Number of subjects: 148
Study 17099008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 15577133 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 15488343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% sevoflurane in O2
Number of subjects: 20
Study 15488343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% sevoflurane in O2
Number of subjects: 20
Study 15488343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% sevoflurane in O2
Number of subjects: 20
Study 15488343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% sevoflurane in O2
Number of subjects: 20
Study 15488343 — intervention group
Group type: COMPARATOR
Intervention: 100% O2 (placebo)
Number of subjects: 20
Study 10425698 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention
Number of subjects: 496
Study 10425698 — intervention group
Group type: COMPARATOR
Intervention: Control intervention on other health issues
Number of subjects: 496
Study 7990870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 17
Study 7990870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure with eyes covered
Number of subjects: 17
Study 2184002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 0
Study 7270761 — intervention group
Group type: EXPERIMENTAL
Intervention: Full benefit group (50% copayment)
Number of subjects: 250
Study 7270761 — intervention group
Group type: COMPARATOR
Intervention: 50% copayment group
Number of subjects: 250
Study 7270761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both payment groups
Number of subjects: 250
Study 7270761 — intervention group
Group type: EXPERIMENTAL
Intervention: Full benefit group
Number of subjects: 250
Study 31670008 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) - twelve 60-s bouts of vibration; frequency 35 Hz; amplitude 4 mm; 1-min rest intervals
Number of subjects: 10
Study 31670008 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 10
Study 30569067 — intervention group
Group type: EXPERIMENTAL
Intervention: Native whey (20 g)
Number of subjects: 21
Study 30569067 — intervention group
Group type: EXPERIMENTAL
Intervention: WPC‐80 (20 g)
Number of subjects: 21
Study 30569067 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 21
Study 28356431 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut meal (3 ounces / 85 g ground peanuts, 1198 kcal)
Number of subjects: 15
Study 28356431 — intervention group
Group type: COMPARATOR
Intervention: Control meal (matched for energy and macronutrient content)
Number of subjects: 15
Study 28356431 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut meal
Number of subjects: 15
Study 25929530 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 21
Study 25929530 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 21
Study 23172174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (USG) for CVC placement
Number of subjects: 0
Study 23172174 — intervention group
Group type: COMPARATOR
Intervention: Anatomic placement (without USG) for CVC placement
Number of subjects: 0
Study 23172174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (USG) for inadvertent arterial puncture
Number of subjects: 0
Study 23172174 — intervention group
Group type: COMPARATOR
Intervention: Anatomic placement (without USG) for inadvertent arterial puncture
Number of subjects: 0
Study 21846957 — intervention group
Group type: EXPERIMENTAL
Intervention: Total face mask
Number of subjects: 60
Study 21846957 — intervention group
Group type: COMPARATOR
Intervention: Oronasal mask
Number of subjects: 60
Study 19911216 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Dif1stat
Number of subjects: 240
Study 19911216 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 240
Study 17890695 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty (PCI)
Number of subjects: 0
Study 17890695 — intervention group
Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 0
Study 17890695 — intervention group
Group type: COMPARATOR
Intervention: Registry data
Number of subjects: 0
Study 15602190 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/day twice a day for 7 days)
Number of subjects: 200
Study 15602190 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 200
Study 15602190 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 200
Study 11511016 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled cold therapy (CCT)
Number of subjects: 72
Study 11511016 — intervention group
Group type: COMPARATOR
Intervention: Ice therapy
Number of subjects: 72
Study 9663245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 240
Study 9663245 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cholangiography (IOC)
Number of subjects: 240
Study 8154629 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge
Number of subjects: 0
Study 8154629 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test (SPT)
Number of subjects: 0
Study 8154629 — intervention group
Group type: COMPARATOR
Intervention: Measurement of specific IgE (RAST)
Number of subjects: 0
Study 8154629 — intervention group
Group type: COMPARATOR
Intervention: Histamine release from basophils (HR)
Number of subjects: 0
Study 31734088 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochromic contact lens (Test)
Number of subjects: 61
Study 31734088 — intervention group
Group type: COMPARATOR
Intervention: Non-photochromic contact lens (Control)
Number of subjects: 61
Study 30151504 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Salvadora persica miswak
Number of subjects: 100
Study 30151504 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 100
Study 30151504 — intervention group
Group type: COMPARATOR
Intervention: Cetylpyridinium
Number of subjects: 100
Study 30151504 — intervention group
Group type: COMPARATOR
Intervention: Extract of Azadirachta indica miswak
Number of subjects: 100
Study 26780085 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 639
Study 24449228 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 66
Study 24449228 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and oral doxycycline (100 mg) administration once daily for 15 days
Number of subjects: 66
Study 24449228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 66
Study 22563948 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipin 2.5 mg once daily
Number of subjects: 32
Study 22563948 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency TENS for 30 min bidaily
Number of subjects: 32
Study 22563948 — intervention group
Group type: COMPARATOR
Intervention: Felodipin
Number of subjects: 32
Study 22563948 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 32
Study 20802205 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lesions in the anterior corpus callosum
Number of subjects: 0
Study 20802205 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 20802205 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lesions in the posterior corpus callosum
Number of subjects: 0
Study 18679411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (increased consumption of cereals, especially breakfast cereals)
Number of subjects: 49
Study 18679411 — intervention group
Group type: COMPARATOR
Intervention: Diet V (increased consumption of vegetables)
Number of subjects: 49
Study 16580190 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (125,000 UI) administered via intrathoracic tube every 12 hours until pleural fluid < 50 cm3
Number of subjects: 29
Study 16580190 — intervention group
Group type: COMPARATOR
Intervention: Simple drainage with suction
Number of subjects: 29
Study 16580190 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (125,000 UI) administered via intrathoracic tube
Number of subjects: 29
Study 12730420 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified beverage containing 11 micronutrients (iron, iodine, zinc, vitamin A, vitamin C, niacin, riboflavin, folate, vitamin B-12, vitamin B-6, and vitamin E) for 8 weeks
Number of subjects: 259
Study 12730420 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified beverage
Number of subjects: 259
Study 10784638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg orally three times a day (tid)
Number of subjects: 154
Study 10784638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 10784638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 154
Study 8729590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily, starting at least 2 weeks before PTCA
Number of subjects: 730
Study 1343609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg daily for 6 months)
Number of subjects: 103
Study 1343609 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (80 mg trimethoprim, 400 mg sulfamethoxazole daily for 6 months)
Number of subjects: 103
Study 1343609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 103
Study 1343609 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 103
Study 4006380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil 450 mg
Number of subjects: 8
Study 4006380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30381582 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A (sun protection factor 50 PA+++)
Number of subjects: 230
Study 30381582 — intervention group
Group type: EXPERIMENTAL
Intervention: Product B (sun protection factor 19 PA+++)
Number of subjects: 230
Study 28488827 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercises
Number of subjects: 132
Study 28488827 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercises
Number of subjects: 132
Study 27825388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian suppression (OFS)
Number of subjects: 1967
Study 27825388 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus ovarian suppression (OFS)
Number of subjects: 1967
Study 27825388 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP19A1/ESR1 genotypes
Number of subjects: 1967
Study 25146603 — intervention group
Group type: EXPERIMENTAL
Intervention: ShengJinRunZaoYangXue granules
Number of subjects: 240
Study 25146603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 23135126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Damon 3MX)
Number of subjects: 30
Study 23135126 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligation brackets
Number of subjects: 30
Study 20229196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy using scissors and raspatory with electrocautery for coagulation (27 patients)
Number of subjects: 60
Study 20229196 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy using pressure‐assisted tissue‐welding technology (33 patients)
Number of subjects: 60